197 related articles for article (PubMed ID: 24198185)
1. Combining antibody-directed presentation of IL-15 and 4-1BBL in a trifunctional fusion protein for cancer immunotherapy.
Kermer V; Hornig N; Harder M; Bondarieva A; Kontermann RE; Müller D
Mol Cancer Ther; 2014 Jan; 13(1):112-21. PubMed ID: 24198185
[TBL] [Abstract][Full Text] [Related]
2. IL15-Based Trifunctional Antibody-Fusion Proteins with Costimulatory TNF-Superfamily Ligands in the Single-Chain Format for Cancer Immunotherapy.
Beha N; Harder M; Ring S; Kontermann RE; Müller D
Mol Cancer Ther; 2019 Jul; 18(7):1278-1288. PubMed ID: 31040163
[TBL] [Abstract][Full Text] [Related]
3. A novel antibody-4-1BBL fusion protein for targeted costimulation in cancer immunotherapy.
Müller D; Frey K; Kontermann RE
J Immunother; 2008 Oct; 31(8):714-22. PubMed ID: 18779748
[TBL] [Abstract][Full Text] [Related]
4. An antibody fusion protein for cancer immunotherapy mimicking IL-15 trans-presentation at the tumor site.
Kermer V; Baum V; Hornig N; Kontermann RE; Müller D
Mol Cancer Ther; 2012 Jun; 11(6):1279-88. PubMed ID: 22491823
[TBL] [Abstract][Full Text] [Related]
5. Evaluating combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy.
Hornig N; Reinhardt K; Kermer V; Kontermann RE; Müller D
Cancer Immunol Immunother; 2013 Aug; 62(8):1369-80. PubMed ID: 23715927
[TBL] [Abstract][Full Text] [Related]
6. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma.
Xu DP; Sauter BV; Huang TG; Meseck M; Woo SL; Chen SH
Gene Ther; 2005 Oct; 12(20):1526-33. PubMed ID: 15973445
[TBL] [Abstract][Full Text] [Related]
7. Combination of a bispecific antibody and costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy.
Hornig N; Kermer V; Frey K; Diebolder P; Kontermann RE; Müller D
J Immunother; 2012 Jun; 35(5):418-29. PubMed ID: 22576347
[TBL] [Abstract][Full Text] [Related]
8. Anti-prostate cancer effects of CTL cell induction in vitro by recombinant adenovirus mediated PSMA/4-1BBL dendritic cells: an immunotherapy study.
Sui CG; Wu D; Meng FD; Yang MH; Jiang YH
Genet Mol Res; 2015 Jun; 14(2):7208-17. PubMed ID: 26125931
[TBL] [Abstract][Full Text] [Related]
9. Bifunctional Fusion Proteins Derived from Tumstatin and 4-1BBL for Targeted Cancer Therapy.
Sun C; He D; Ma C; Gao Z; Chen Y; Wang S
Mol Pharm; 2019 Feb; 16(2):867-876. PubMed ID: 30565463
[TBL] [Abstract][Full Text] [Related]
10. 4-1BB (CD137) ligand enhanced anti-tumor immune response against mouse forestomach carcinoma in vivo.
Li Q; Ai J; Song Z; Liu J; Shan B
Cell Mol Immunol; 2008 Oct; 5(5):379-84. PubMed ID: 18954562
[TBL] [Abstract][Full Text] [Related]
11. Long-term proliferation of functional human NK cells, with conversion of CD56(dim) NK cells to a CD56 (bright) phenotype, induced by carcinoma cells co-expressing 4-1BBL and IL-12.
Dowell AC; Oldham KA; Bhatt RI; Lee SP; Searle PF
Cancer Immunol Immunother; 2012 May; 61(5):615-28. PubMed ID: 22021067
[TBL] [Abstract][Full Text] [Related]
12. Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy.
Liu M; Wang H; Liu L; Wang B; Sun G
J Transl Med; 2016 Jun; 14(1):155. PubMed ID: 27246873
[TBL] [Abstract][Full Text] [Related]
13. Development of an antibody-ligand fusion protein scFvCD16A
Li Y; Xie S; Chen M; Li H; Wang Y; Fan Y; An K; Wu Y; Xiao W
Microb Cell Fact; 2023 Apr; 22(1):67. PubMed ID: 37041591
[TBL] [Abstract][Full Text] [Related]
14. A novel adenovirus expressing human 4-1BB ligand enhances antitumor immunity.
Yoshida H; Katayose Y; Unno M; Suzuki M; Kodama H; Takemura S; Asano R; Hayashi H; Yamamoto K; Matsuno S; Kudo T
Cancer Immunol Immunother; 2003 Feb; 52(2):97-106. PubMed ID: 12594573
[TBL] [Abstract][Full Text] [Related]
15. Production of recombinant human trimeric CD137L (4-1BBL). Cross-linking is essential to its T cell co-stimulation activity.
Rabu C; Quéméner A; Jacques Y; Echasserieau K; Vusio P; Lang F
J Biol Chem; 2005 Dec; 280(50):41472-81. PubMed ID: 16204238
[TBL] [Abstract][Full Text] [Related]
16. CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand.
Saoulli K; Lee SY; Cannons JL; Yeh WC; Santana A; Goldstein MD; Bangia N; DeBenedette MA; Mak TW; Choi Y; Watts TH
J Exp Med; 1998 Jun; 187(11):1849-62. PubMed ID: 9607925
[TBL] [Abstract][Full Text] [Related]
17. Enhanced function of cytotoxic T lymphocytes induced by dendritic cells modified with truncated PSMA and 4-1BBL.
Youlin K; Li Z; Xin G; Mingchao X; Xiuheng L; Xiaodong W
Hum Vaccin Immunother; 2013 Apr; 9(4):766-72. PubMed ID: 23295983
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL.
Huang JH; Zhang SN; Choi KJ; Choi IK; Kim JH; Lee MG; Lee M; Kim H; Yun CO
Mol Ther; 2010 Feb; 18(2):264-74. PubMed ID: 19738604
[TBL] [Abstract][Full Text] [Related]
19. Tumor-specific crosslinking of GITR as costimulation for immunotherapy.
Burckhart T; Thiel M; Nishikawa H; Wüest T; Müller D; Zippelius A; Ritter G; Old L; Shiku H; Renner C
J Immunother; 2010; 33(9):925-34. PubMed ID: 20948444
[TBL] [Abstract][Full Text] [Related]
20. An engineered 4-1BBL fusion protein with "activity on demand".
Mock J; Stringhini M; Villa A; Weller M; Weiss T; Neri D
Proc Natl Acad Sci U S A; 2020 Dec; 117(50):31780-31788. PubMed ID: 33239441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
